Drug firm Zydus Cadila on Friday said it has received approval from Mexico's regulatory authority Cofepris to conduct clinical trials
New Delhi: Drug firm Zydus Cadila on Friday said it has received approval from Mexico's regulatory authority Cofepris to conduct clinical trials in the Latin American country with its biological therapy "Pegylated Interferon alpha-2b" for treatment of Covid-19.
CoronavirusClinical and regulatory development of the therapy in Covid-19 is being executed in Mexico by Avant Sant Research Center S.A. de C.V., a contract research organisation (CRO) headquartered in Monterrey, Mexico.
Zydus Cadila said it had received approval from the Mexican regulatory authority Cofepris to conduct clinical trials with its biological therapy, Pegylated Interferon alpha-2b, 'PegiHepTM'.
It added that this will be an open-label, randomised, comparator controlled study to evaluate safety, efficacy and tolerability in patients with Covid-19.
Covid-19 vaccineZydus had earlier approached the Drug Controller General of India to investigate the role of Pegylated Interferon alpha-2b for Covid-19 and the clinical trials are now underway, the company said.
